DS-2325a

DB18134InvestigationalGene Therapies

DS-2325a is an inhibitor of kallikrein 5 under development for the treatment of Netherton Syndrome.

Mechanism
Curator reviewed
Code names
DS-2325a

Resolves to

Compound
UNIIS9CR2ZV5Z4
Targets
Q9Y337KLK5

What you can answer from here — as of October 05, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
2Clinical trialsPhase, status and sponsor resolved per trial
Sign in
2+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with DS-2325a, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In